AI research is central to many of the deals. In April, French pharmaceutical giant Sanofi announced a $1.7 billion agreement ...

Out-licensing drugs to multinational corporations is a natural step for Chinese biotechs, but the recent rise in deals is ...

Trump's pharma tariffs haven't appeared yet, but AstraZeneca has joined several of its peers with big investments in US manufacturing and R&D.